The primary mammalian circadian clock, located in the suprachiasmatic nuclei (SCN), receives a major input from the raphe nuclei. The role of this input is largely unknown, and is the focus of this research. The SCN clock survives in vitro, where it produces a 24-hr rhythm in spontaneous neuronal activity that is sustained for at least three cycles. The sensitivity of the SCN clock to drugs can therefore be tested in vitro by determining whether various compounds alter the phase of this rhythm. We have previously shown that the nonspecific serotonin (5-HT) agonist quipazine resets the SCN clock in vitro, inducing phase advances in the daytime and phase delays at night. These results suggest that the 5-HT-ergic input from the raphe nuclei can modulate the phase of the SCN circadian clock. In this study we began by using autoradiography to determine that the SCN contain abundant 5-HT 1A and 5-HT 1B receptors, very few 5-HT 1C and 5-HT 2 receptors, and no 5-HT 3 receptors. Next we investigated the ability of 5-HT-ergic agonists and antagonists to reset the clock in vitro, in order to determine what type or types of 5-HT receptor(s) are functionally linked to the SCN clock. We began by providing further evidence of 5-HT-ergic effects in the SCN. We found that 5-HT mimicked the effects of quipazine, whereas the nonspecific 5-HT antagonist metergoline blocked these effects, in both the day and night. Next we found that the 5-HT 1A agonist 8-OH-DPAT, and to a lesser extent the 5-HT 1A-1B agonist RU 24969, mimicked the effects of quipazine during the subjective daytime, whereas the 5-HT 1A antagonist NAN-190 blocked quipazine's effects. None of the other specific agonists or antagonists we tried induced similar effects. This suggests that quipazine acts on 5-HT 1A receptors in the daytime to advance the SCN clock. None of the specific agents we tried were able either to mimic or to block the actions of 5-HT or quipazine at circadian time 15. Thus, we were unable to determine the type of 5-HT receptor involved in nighttime phase delays by quipazine or 5-HT. However, since the dose-response curves for quipazine during the day and night are virtually identical, we hypothesize that the nighttime 5-HT receptor is a 5-HT 1 -like receptor.
suprachiasmatic nuclei (SCN) (Turek, 1985) . The endogenous pacemaking characteristics of this circadian clock have been demonstrated in vitro. Various studies have shown that the SCN continue to produce 24-hr rhythms in metabolism (Schwartz and Gainer, 1977; Schwartz et al., 1980) , vasopressin secretion (Earnest and Sladek, 1986) , and neuronal activity (Green and Gillette, 1982) after being isolated from the rest of the brain and in the absence of external timing information. In the case of the neuronal activity rhythm, this oscillation continues for three cycles in vitro, with a phase (determined by the time of the peak in neuronal activity) that is consistent from cycle to cycle and from animal to animal (Gillette, 1986; . In addition to confirming the endogenous nature of the SCN circadian clock, the expression of this clear and precise rhythm in vitro allows the clock to be studied in isolation.
Although the SCN clock produces 24-hr rhythms in the absence of timing information, it normally receives input from a variety of brain regions. Apart from the visual input it receives through the retinohypothalamic and geniculohypothalamic tracts (Moore and Lenn, 1972; Swanson et al., 1974; Pickard, 1982) , the largest afferent input to the SCN is the serotonergic (5-HT-ergic) projection from the midbrain raphe nuclei (Aghajanian et al., 1969; Moore et al., 1978) . Earlier studies have suggested that this projection can modulate SCN clock functioning, although it is not essential for the clock to operate. Some studies found that raphe lesions or chemical treatments that deplete brain 5-HT levels decrease the amplitude (Block and Zucker, 1976; Kam and Moberg, 1977; Szafarczyk et al., 1979) or change the phase (Honma et al., 1979; Williams et al., 1983; Smale et al., 1990) of circadian rhythms, although other studies found these treatments to have no effect on circadian rhythms (Moore and Klein, 1974; Balestrery and Moberg, 1976 ). In addition, injections of a monoamine oxidase inhibitor or 5-HT uptake blocker, both of which increase 5-HT levels, can phase-shift circadian rhythms in vivo (Wirz-Justice and Campbell, 1982) . Taken together, these results support the conclusion that 5-HT can alter clock activity. However, it is not clear whether the changes in 5-HT affect the clock through direct actions in the SCN, or whether the effects on the clock are the indirect result of 5-HT-ergic actions in other brain regions.
If 5-HT affects the clock by direct actions in the SCN, there are many receptor types through which it could potentially act. The family of 5-HT receptors at this point has been divided into four general types (5-HT1_4), and the 5-HT, type has been further divided into at least four subtypes (5-HTIA-ID). As part of the present study, we have used autoradiography to determine which of these receptors are localized in the SCN. Our results indicate the presence of abundant 5-HT1A and 5-HT1B receptors, and small numbers of 5-HTc and 5-HT2 receptors in the SCN.
In order to determine whether 5-HT can directly modulate the SCN clock and through what receptor type(s) it acts, we have been investigating the ability of 5-HT agonists and antagonists to reset the SCN clock in vitro. Previous work has shown that the SCN clock can be reset in vitro by bath application of a variety of agents, including analogues of the intracellular second messengers cyclic adenosine monophosphate (cyclic AMP) ) and cyclic guanosine monophosphate (cyclic GMP) , as well as 5-HT (Medanic and Gillette, 1992) and melatonin (McArthur et al., 1991) .
Furthermore, we showed that the SCN clock is sensitive to in vitro resetting by the nonspecific 5-HT agonist quipazine (Prosser et al., 1990) , and that this effect is both dose-dependent and phase-specific. Expanding on these results, in the present study we have addressed two critical questions: (1) What types of 5-HT receptors are functionally linked to the SCN clock? and (2) When is the SCN clock sensitive to stimulation of these receptors?
Our results suggest that there are at least two 5-HT receptor types functionally coupled to the SCN clock: the 5-HT1A receptor and a previously uncharacterized 5-HT receptor. Furthermore, stimulation of these two receptor subtypes may be responsible, respectively, for daytime phase advances and nighttime phase delays of the SCN clock by 5-HT-ergic agents.
METHODS

AUTORADIOGRAPHY
Adult male Wistar rats, housed in a light-dark cycle (LD 12:12) , were sacrificed at circadian time (CT) 6 or CT 18 for these experiments. Animals were anesthetized briefly with chloroform and perfused intracardially through the left ventricle with ice-cold saline for 5-10 min. Subsequently the brains were quickly removed and frozen in isopentane maintained at -30°C. Sections 15 Rm thick were cut at -20°C and mounted on slides coated with 0.5% gelatin and 0.05% chromium potassium sulfate. Sections from each brain were stained with cresyl violet and examined under the light microscope in order to bracket those sections containing the SCN. (1990). [3H]quipazine was used to label 5-HT3 receptors according to the methods of Milburn and Peroutka (1989) . e25I]LSD (0.05-0.1 mvt) (2200 Ci/mmol, Dupont New England Nuclear) was used to label 5-HTic and 5-HT2 receptors. To preferentially label 5-HTIC receptors, unlabeled spiperone (50 nM) was added to mask the 5-HT2 receptors. The density of 5-HT2 receptors was determined by subtracting the 5-HT1c binding from the total binding. The nonspecific binding was determined by incubating adjacent sections under identical conditions, but in the presence of 100 nM mianserin, which displaced the 5-HT2 and 5-HTic receptors. The labeling was carried out in 50 mM Tri buffer (pH 7.4) for 60 min in the presence of 10 nM domperidone to mask any binding to dopamine D2 receptors. Labeling was followed by three 20-min washes in ice-cold Tris buffer (pH 7.4), and a quick dip in double-distilled H20.
5-HTIA receptors
ELECTROPHYSIOLOGY
The methods used in these experiments have been published previously in detail . Briefly, 500-Rm coronal brain slices containing the paired SCN were prepared during lights-on from adult male Wistar rats housed in LD 12:12. Slices were maintained in a Hatton-style brain slice chamber (Hatton et al., 1980) warmed to 37°C and gassed continuously with 95% 02/5% C02. The slices were continuously perfused at 35 ml/ hr with warm, oxygenated Earle's Balanced Salt Solution (Sigma), supplemented with 24.6 mM glucose and 26.2 mM sodium bicarbonate (pH 7.4). For slices maintained longer than 36 hr, the medium was further supplemented with 0.05% gentamicin. We have shown that under these conditions SCN slices remain viable for up to 60 hr, during which time they continue to show robust, spontaneous neuronal activity .
All compounds tested for their ability to affect the clock were dissolved in the normal perfusion medium, except metergoline, which was initially dissolved in ethanol and then diluted with the medium so that the final concentration of ethanol was less than 1% (a concentration found not to phase-shift the SCN in vitro). The concentrations of the various compounds used were chosen to fall within the physiological range (typically 1-10 yvt) . Furthermore, specific concentrations were chosen to significantly exceed published Kd's and K,'s for the relevant receptors, while avoiding nonspecific effects at other sites. To apply the compounds, perfusion of the slice chamber was stopped at the specified time, and the perfusion medium in the chamber was removed and replaced with medium containing the test substance. At the end of 1 hr this test medium was removed and replaced with the normal medium, and perfusion was reinstated. For blocking experiments the same procedure was used, except that normal medium was first replaced with medium containing the antagonist agent. After 15 min this medium was replaced for 1 hr with medium containing both the antagonist and agonist compounds, after which the antagonist-containing medium was applied for another 15 min, followed by the normal perfusate medium. All treatments were performed during the first circadian cycle in vitro.
The ability of each treatment to reset the clock was determined by monitoring the rhythm of spontaneous neuronal activity during the one or two circadian cycles following treatment. The neuronal activity of single SCN neurons was monitored extracellularly with glass electrodes filled with 3 M NaCl. Activity from cells with signals at least twice the level of background noise was recorded for 5 min. All data were stored for later determination of firing rates using a Brain Wave data collection and analysis system. The firing rates of individual cells were then averaged over 2-hr intervals, with 1-hr lags, to determine the time of the peak in the averaged neuronal activity rhythm. The peak was defined as the symmetrically highest point, and estimated to the closest quarter hour. We have found that this time of peak is a reliable marker of the phase of the underlying circadian pacemaker Prosser et al., 1990) . Phase shifts were determined by comparing the time of peak in treated slices to that of untreated control slices, since the treatment protocol itself does not affect the phase of the rhythm (Prosser et al., 1990) . Only changes in the time of peak that were greater than 1 hr were considered significant, since this exceeds the normal range of variation seen in untreated slices (mean time of peak = CT 6.0 ± 0.32 hr, n = 5, where CT 0 is the time of lights-on in the donor colony).
Chemicals used in this study were quipazine maleate (Miles Laboratories, Inc.); metergoline (Farmitalia); RU 24969 (generous gift of Dr. R. Ciaranello); 5-hydroxytryptamine creatine sulfate (5-HT, Sigma); BRL 24924 (Smith, Kline and Beecham); and ( ± )-8-OH-DPAT-HBr, CGS 12066B dimaleate, 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane HBr (DOB), 3-tropanyl-indole-3-carboxylate , (Research Biochemicals, Inc.) .
RESULTS
AUTORADIOGRAPHY
Our [3H]8-OH-DPAT results indicated very high 5-HT IA binding throughout the SCN, as well as much of the surrounding anterior hypothalamus. e25I]LSD studies showed very little 5-HT2 and 5-HT,c binding in the SCN and surrounding areas. The results of [3H]quipazine studies showed no 5-HT3 receptors in the SCN. These results are summarized in Table 1. Comparison of the receptor binding in animals sacrificed at CT 6 versus CT 18 (Table  1) showed no day-night differences in 5-HTIA binding, whereas 5-HT1B receptor binding was significantly higher during the night than during the day. A small but statistically significant elevation in 5-HT2 binding occurred at CT 18, whereas no differences were seen in 5-HTIc binding.
SEROTONERGIC BASIS OF PHASE-SHIFTING EFFECTS
We previously showed that the nonspecific 5-HT agonist quipazine can reset the SCN clock in vitro, inducing phase advances in the subjective day and phase delays during the subjective night (Table 2; Prosser et al., 1990) . We chose to use quipazine as our primary 5-HT-ergic agent because it is a general 5-HT agonist with at least micromolar affinity for the known 5-HT receptors (Hoyer et al., 1985) , but is not rapidly oxidized as 5-HT itself is. To substantiate that these effects are the result of quipazine acting at 5-HT-ergic receptors, we performed several sets of experiments. We tried to mimic the effects of quipazine with the endogenous compound 5-HT; we tried to block the effects of quipazine with a nonspecific 5-HT antagonist, metergoline; and we investigated the dose responsiveness of the SCN clock to quipazine at night, in order to compare it with the clock's sensitivity to quipazine in the daytime.
One-hour treatments with 1 Rm 5-HT (with 0.1 mM perchloric acid to prevent oxidation) mimicked the effects of quipazine at both CT 6 and CT 15, inducing 4-hr phase advances and 3-hr phase delays at these two times, respectively ( Fig. 1 , Table 2 ). Perchloric acid alone, however, had no effect at either time (Table 2) .
One-hour treatment with the nonspecific 5-HT antagonist metergoline (10 (JLM) by itself at CT 6 and CT 15, the times when quipazine induces maximal advances and delays, Note. The data are presented as the mean --t SEM (hr) phase advances (+) and delays (-) in the in vitro neuronal activity rhythm induced by the compounds listed. When n = 2, the SEM equals the SD.
respectively, had no effect on the phase of the clock (Table 2 ). In each case, the subsequent peak in neuronal activity occurred near the normal time (CT 6). Metergoline did, however, induce small delays of 1.25 to 2 hr when applied at CT 12, a time when quipazine has no effect on the clock (Table 2) . When metergoline and quipazine were applied together at either CT 6 or CT 15, metergoline completely blocked the phase shifts normally induced by quipazine alone (Fig. 2 , Table 2 ). In both cases the time of peak neuronal activity during FIGURE 1. Serotonin mimics the effects of quipazine in vitro. Shown are the 2-hr means ± SEMs of neuronal activity after treatment with 1 )JLM serotonin. Top: Serotonin treatment at CT 6 induced a 4hr phase advance in the neuronal activity rhythm. Bottom: Serotonin treatment at CT 15 induced a 3hr phase delay in the neuronal activity rhythm. These effects are similar to those of quipazine at these times. Hatched bar: Time of treatment. Solid bar: Time of lights-off in the donor animal colony. Dotted line: Mean time of peak in untreated slices. the cycle following treatment occurred near CT 6. These results further support the hypothesis that quipazine acts on the SCN clock through stimulation of 5-HT receptors.
In our previous study, we showed that the daytime (CT 6) effects of quipazine are dosedependent, with an EDso (dose inducing half-maximal phase shifts) of 0.5 yvt (Fig. 3 and Prosser et al., 1990) . To begin our comparison of daytime versus nighttime actions on 5-HT receptors, we determined the dose-response curve for quipazine at CT 15. In these experiments we determined the magnitude of the phase shift induced by different concentrations of quipazine applied at CT 15. The results of these experiments, shown in Figure 3 , indicate that the ED50 for quipazine at CT 15 is also about 0.5 p,M. From these dose-response curves we determined that an appropriate concentration of quipazine to use in blocking experiments (such as described above) was 1 yvt, twice the EDso. The Hill plots (Fig. 3, inset) derived from the dose-response curves have slopes of 0.67; this finding suggests that the effects of quipazine may involve some negative cooperativity between sites occupied by quipazine at either CT. These results further indicate that the SCN clock is equally sensitive to resetting by quipazine at CT 6 and CT 15, and suggest that quipazine may act on similar receptor types at these two times. 
DAYTIME PHASE ADVANCE
In order to determine the type(s) of 5-HT receptor(s) involved in the phase advances induced by quipazine, we investigated the ability of a variety of more selective 5-HT agonists to mimic the effects of quipazine at CT 6. When agonists for a specific receptor type were not available, we tested the ability of specific 5-HT antagonists to block the phase shifts induced by quipazine.
The relatively selective 5-HT1A agonist 8-OH-DPAT (Hoyer, 1988; Van Wijngaarden et al., 1990) , at a concentration of 10 J.LM, was found to induce 3-hr phase advances in the SCN neuronal activity rhythm, so that the time of peak during the cycle following treatment occurred at CT 3 (Fig. 4 , Table 2 ). These shifts are similar to those induced by quipazine treatment at this time. Similar effects were obtained after treatment with another 5-HTIA agonist, buspirone (Table 2) . We also investigated the actions of the 5-HTIA antagonist NAN-190 (Glennon et al., 1988; Van Wijngaarden et al., 1990 ) at CT 6. NAN-190 was unable to induce phase shifts when applied by itself at concentrations of 100 nM and 10 yvt, but it was able to block the phase advances induced by 1 J.LM quipazine at this time FIGURE 3. Dose-response curve for quipazine at CT 6 and CT 15. Shown are the phase shifts (advances for CT 6, delays for CT 15) induced by different concentrations of quipazine applied to SCN slices. Symbols indicate the results from single experiments; solid line connects the means for each concentration (data for CT 6 replotted from Prosser et al., 1990) . In both cases, the EDso for quipazine is approximately 0.5 I-LM. Inset: Hill plots of the same data. Slopes for both sets of data equal 0.67. (Fig. 4 , Table 2 ). Although the concentrations of 8-OH-DPAT and NAN-190 used here are considerably higher than their affinities for the 5-HT1A receptor (Kd for 8-OH-DPAT = 2.0 nNt, Hoyer et al., 1985; Kl for NAN-190 = 0.58 nM, Glennon et al., 1988), they are comparable to the effective concentrations attained in behavioral and electrophysiological studies showing 5-HT1A selective effects (Berendsen et al., 1989; Glennon et al., 1988) . Taken together, these results suggest that the actions of quipazine on the SCN clock at CT 6 occur largely through stimulation of 5-HT1A receptors.
Two agents were used to investigate the ability of 5-HT1B receptors to influence the SCN clock. RU 24969 (10 ~.~,M), an agonist with equal affinity for the 5-HT1A and 5-HT1B receptors (Hoyer, 1988) , induced variable phase advances (1.25-3 hr) when applied at CT 6 ( Table 2 ). However, CGS 12066B, administered at a dose (0.3 Rm) selective for the 5-HTIB receptor (Neale et al., 1987) , had little effect on the SCN clock (Table 2 ). Together, these results suggest little or no role for 5-HT1B receptors in resetting by quipazine at CT 6.
One-hour treatment with 1 wNt DOB, a 5-HT agonist with relatively high affinities for both the 5-HTic and 5-HT2 receptors (Peroutka et al., 1988) , had no effect on the phase of the neuronal activity rhythm when applied to SCN slices at CT 6 ( Table 2 ). There are no selective 5-HT3 or 5-HT4 agonists, but ICS 205-930, at 5 ~,M, is a relatively selective antagonist for these two receptor types (Richardson et al., 1985; Dumuis et al., 1988) . We found 1-hr treatment with ICS 205-930 to have no effect on the SCN clock when applied by itself at CT 6, nor did it block the phase shifts induced by 1 pLM quipazine at this time (Table 2) . Thus, none of these 5-HT receptors appear to be involved in daytime resetting by quipazine. NIGHTIME PHASE DELAYS Before investigating the role of specific 5-HT receptor types in the nighttime actions of quipazine on the SCN clock, we needed to provide additional evidence that the phase delays induced by quipazine were permanent, as we have previously shown for quipazine-induced phase advances (Prosser et al., 1990) . Therefore, we monitored the neuronal activity rhythm of the SCN clock for 2 days after applying quipazine to the slices at CT 15. As shown in Figure 5 , the delayed time of peak (at CT 9.5) seen one cycle following treatment is repeated in the second cycle following treatment (again at CT 9.5). These results provide strong evidence that the phase delay induced by quipazine is permanent, and that it reflects a shift in the underlying circadian clock.
Having determined that quipazine induces long-lasting phase shifts at night, we attempted to determine what 5-HT receptor type or types were involved in these actions. As with the phase advances, we tested a variety of specific 5-HT agonists and antagonists to determine their ability to mimic or block the effects of quipazine at CT 15.
One-hour treatment with 10J.LM 8-OH-DPAT did not induce phase delays when applied at CT 15 (Fig. 6 , Table 2 ). Furthermore, the 5-HTIA antagonist unable to block the phase delays induced by quipazine at this time (Fig. 6 , Table 2 ). Thus, in contrast to the results with daytime phase advances, the 5-HTIA receptor does not appear to be involved in the phase delays induced by quipazine at CT 15. FIGURE 5. Quipazine induces long-lasting phase shifts at night. Shown are the means ± SEMs of the neuronal activity rhythm for two cycles following treatment with 10 u.M quipazine at CT 15. The delayed time of peak seen during the first cycle following treatment (CT 9.5) was also seen during the second cycle following treatment. Therefore, the underlying circadian clock appears to have been shifted by this treatment. See Figure 1 legend for details.
Neither 10 yvt RU 24969 nor 0.3 yvt CGS 12066B was able to reset the SCN clock when applied for 1 hr at CT 15 (Table 2 ). These results suggest that, as with daytime phase advances, quipazine does not phase-delay the clock by acting on 5-HT1B receptors.
The 5-HTIc-2 agonist DOB (1 Rm) did not change the phase of the SCN neuronal activity rhythm when applied for 1 hr at CT 15 (Table 2 ). In addition, the 5-HT3_4 antagonist ICS 205-930 (5 J.LM) had no effect alone, and did not inhibit the ability of quipazine to FIGURE 6. Nighttime effects of 5-HTIA agents. Shown are the effects of the 5-HTIA agonist 8-OH-DPAT (10 yvt) and antagonist (100 nM phase-delay the SCN clock at CT 15 (Table 2) . Thus, these receptor types appear not to be involved in either the daytime or the nighttime phase shifts induced by quipazine.
In our search to find a 5-HT receptor through which quipazine could act at night, we investigated the more recently characterized 5-HTIP receptor, using an antagonist specific for this receptor (BRL 24924; Mawe et al., 1986 Mawe et al., , 1989 . We found that BRL 24924 had no effect by itself at CT 15, nor did it block the effects of quipazine at CT 15 (Table 2) .
DISCUSSION
These experiments were attempts to characterize the types of 5-HT receptors present in the SCN and to determine which of these are functionally coupled to the SCN circadian clock. That is, we wanted to determine what receptors were stimulated by 5-HT and the nonspecific 5-HT agonist quipazine in order to produce the phase advances and phase delays induced at CT 6 and CT 15, respectively.
Our results support the conclusion that quipazine phase-advances the SCN clock during the daytime by stimulating 5-HT1A receptors, and that it phase-delays the clock at night though an unidentified 5-HT receptor type. This latter receptor must be a 5-HT receptor, since 5-HT produces a response identical to that of quipazine, and the quipazine response is potently antagonized by the general 5-HT antagonist metergoline. Despite the fact that the 5-HTIA agonist 8-OH-DPAT induces phase shifts during the day and not the night, the SCN clock shows a nearly identical sensitivity to quipazine at both CT 6 and CT 15, suggesting that quipazine may act on similar types of 5-HT receptors at both of these times. The Hill plots for quipazine at the two CTs have slopes of less than 1; this finding suggests that quipazine's actions involve negative cooperativity between at least two 5-HT receptors at each CT. This could be the result of quipazine's acting on two different receptors concurrently-one that acts to induce the phase shifts, and another that acts to partially inhibit the shifts.
The autoradiographic results are consistent with the results of our phase-shifting experiments. We found evidence for the presence of abundant 5-HTIA and 5-HTIB receptors in the SCN, but found very few 5-HT2 and almost no 5-HTIC receptors. Since no variation in 8-OH-DPAT binding was observed at CT 6 versus CT 18, the failure of 8-OH-DPAT to produce phase delays cannot be explained by a change in 5-HTIA receptor density. Rather, this failure could reflect a nocturnal coupling deficit between the 5-HT1A receptor and secondor even third-messenger systems.
Evidence from a variety of studies suggests that not all 5-HT receptor types have yet been accounted for. There is radioligand evidence for an uncharacterized 5-HT binding site in the rat spinal cord (Zemlan et al., 1990) , and biochemical evidence that 5-HT increases cyclic AMP levels in NCB-20 cells (Cossery et al., 1990; Conner and Mansour, 1990 ) and rat cortex (Fayolle et al., 1988) through stimulating uncharacterized 5-HT receptor sites. In addition, there is evidence from biochemical (De Vivo and Maayani, 1990) as well as molecular (Libert et al., 1989) studies for more than one type of 5-HT~A receptor. Such evidence is compatible with the results obtained here; an additional 5-HT1A receptor subtype may mediate the actions of quipazine on the SCN clock at night. Such a receptor would necessarily have relatively low affinity for 8-OH-DPAT compared to either 5-HT or quipazine. In any event, the final determination of the 5-HT receptors that are functionally coupled to the SCN circadian clock must await the further characterization of the 5-HT receptor family.
Other studies have found evidence for pharmacological heterogeneity in certain of the mechanisms of phase advances and delays. For example, light-induced phase advances, but not phase delays, can be blocked by the benzodiazepine diazepam (Ralph and Menaker, 1986) . Conversely, light-induced phase delays, but not phase advances, can be blocked by the 'Y-aminobutyric acid (GABA) antagonist bicuculline (Ralph and Menaker, 1985) . How common it is for stimuli to induce phase advances and delays through different physiological mechanisms is not known.
Previous work in our laboratory has shown that quipazine induces both phase advances and phase delays in the presence of 1 yvt tetrodotoxin (TTX) or 10 mM Mg 2+_treatments that block Na+-dependent action potentials and Ca2+-dependent neurotransmitter release, respectively (Prosser et al., 1992) . These results suggest that the receptors through which quipazine acts to reset the SCN clock are located on clock cells or on cells that communicate to the clock through nonsynaptic mechanisms (e.g., gap junctions).
The results from this study agree at least in part with those of several recent studies. Edgar et al. (this issue) found that quipazine in vivo induced phase advances and phase delays in the day and night, respectively, qualitatively similar to those we found in vitro, whereas 8-OH-DPAT only induced phase advances. Tominaga et al. (1992) also found that 8-OH-DPAT phase-shifted the clock during the day in vivo but not at night. Interestingly, Medanic and Gillette (1992) found, like us, that 5-HT induced daytime advances in vitro, but they did not find 5-HT to induce phase delays at night. However, they applied the 5-HT by microdrop onto just the ventrolateral portion of the SCN, rather than bath-applying the drugs as we did. Since 5-HT receptors are found throughout the SCN (Van Den Pol and Tsujimoto, 1985) , the differences in our results suggest that the phase delays could be the result of stimulating 5-HT receptors in a different part of the SCN. However, our results with TTX suggest that these receptors must still be either on clock cells or on cells communicating with the clock through gap junctions. The discrepancies between our results require further investigation.
The pattern of phase advances induced by quipazine during the subjective daytime, which appears to be primarily the result of stimulating 5-HT IA receptors, is similar to that induced by analogs of the intracellular second messenger cyclic AMP . Furthermore, stimulation of 5-HTIA receptors in the hippocampus increases basal cyclic AMP levels (Barbaccia et al., 1983; Shenker et al., 1983) . These results suggest that the mechanism underlying daytime 5-HT-ergic phase advances may involve stimulation of S-HT1A receptors, which in turn increases intracellular cyclic AMP levels. This hypothesis could be tested by determining whether 5-HT-ergic agents increase cyclic AMP levels in the SCN, and whether blocking such an increase prevents 5-HT-ergic phase shifts.
Interestingly, the pattern of phase shifts produced by 5-HT and quipazine in the SCN is very similar to that produced by 5-HT in the circadian oscillator in the eye of Aplysia (Corrent et al., 1978) . Furthermore, it appears that 5-HT may induce phase shifts in Aplysia through increasing the level of cyclic AMP, since 5-HT increases cyclic AMP levels in that system and analogues of cyclic AMP mimic the phase shifts induced by 5-HT (Eskin et al., 1982) .
The results from this study support the conclusion that the 5-HT-ergic projection from the raphe to the SCN can modulate the phase of the SCN clock. This is in agreement with previous work showing that treatments that increase or decrease 5-HT activity can induce phase shifts (Honma et al., 1979; Witz-Justice and Campbell, 1982; Williams et al., 1983; Smale et al., 1990 ). In addition, previous studies have demonstrated increased 5-HT activity in the SCN at night (Hery et al., 1982; Faradji et al., 1983; Ramirez et al., 1987) . It is therefore possible that this nightly increase in 5-HT activity may normally act to delay the SCN clock on a cyclic basis. This could explain the advanced phase of entrainment seen in animals after 5-HT-depleting treatments (Smale et al., 1990) .
Activity of raphe neurons has been linked to arousal state, with increased raphe activity associated with increased arousal (McGinty and Szymusiak, 1988) . Several studies have suggested that increased activity or arousal can induce phase shifts in the circadian rhythms of animals (Edgar et al., 1988; Reebs and Mrosovsky, 1989; Edgar and Dement, 1991) . Furthermore, the pattern of phase shifts seen in such studies is qualitatively similar to that seen in this study. This suggests that one possible mechanism through which increased arousal may affect the SCN clock is through increasing 5-HT release in the SCN. This possibility could be investigated by determining whether increased arousal induces phase shifts after depletion of 5-HT levels in the SCN.
In conclusion, we have found that the 5-HT agonist quipazine appears to induce phase shifts of the SCN clock by acting on at least two 5-HT receptor types. It appears to act primarily on 5-HTIA receptors to induce phase advances at CT 6, whereas it acts on an uncharacterized 5-HT receptor, possibly of the 5-HT, subtype, to induce phase delays at night. (1979) Effects of parachlorophenylalanine and 5,6-dihydroxytryptamine on the free-runmng rhythms of locomotor activity and plasma corticosterone in the rat exposed to continuous light. Brain Res. 169: 531-544.
